Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (Symbol: NTRA) is a leading diagnostic and research company based in San Carlos, CA, driven by a commitment to advance the science and application of prenatal testing. In the information age, medical diagnostics have lagged behind in adopting new technologies, but Natera is changing that narrative. The company specializes in preconception and prenatal genetic testing services, providing couples with crucial information throughout the pregnancy journey.
Natera offers a comprehensive range of tests, including Preimplantation Genetic Diagnosis (PGD) for IVF and Non-Invasive Prenatal Testing (NIPT). Their Panorama NIPT is particularly notable for its ability to screen for chromosomal abnormalities in a fetus, even in twin pregnancies, typically through a simple blood draw from the mother. Another significant product is the Horizon Carrier Screening (HCS), which determines carrier status for numerous severe genetic diseases that could be passed on to offspring.
The company's innovative approach leverages advances from the Human Genome Project and is powered by proprietary bioinformatics algorithms. This technology enables highly accurate genetic testing results. Natera's portfolio also includes the Signatera Molecular Residual Disease (MRD) Test, designed to detect circulating tumor DNA in cancer patients, helping to assess molecular residual disease and monitor recurrence. Additionally, the Prospera test assesses organ transplant rejection.
Through its pioneering genetic testing services and experienced genetic counseling, Natera provides valuable insights that help in informed decision-making for pregnancies and medical conditions. The company continues to make significant strides in the field of medical diagnostics, driven by a passion for innovation and excellence.
Natera (NASDAQ: NTRA) has launched DECIPHER, a Phase II, single-arm trial using its Signatera™ test to guide treatment in gastroesophageal cancer patients. This study, the first to evaluate the HER2-directed antibody-drug conjugate for such patients, aims to enroll 25 participants from over 10 UK sites. Patients showing molecular residual disease (MRD) positivity after neoadjuvant chemotherapy and surgery will receive investigational therapy for up to eight cycles instead of the standard adjuvant chemotherapy. Signatera will monitor MRD clearance, the primary endpoint. Previous data showed high disease progression risk for Signatera-positive patients post-standard treatment. DECIPHER aims to offer these patients a better chance at cure.
Natera (NASDAQ: NTRA) has launched an enhanced version of its Prospera Heart™ test, integrating a Donor Quantity Score (DQS) to better detect heart transplant rejection. Traditional dd-cfDNA tests only measure rejection risk based on the fraction of dd-cfDNA in the blood, potentially skewed by unrelated factors. DQS normalizes these readings, improving the accuracy of rejection detection for both acute cellular rejection (ACR) and antibody-mediated rejection (AMR).
In a study involving 703 plasma samples, the DQS-enhanced Prospera Heart test showed improved performance metrics: sensitivity increased from 80.0% to 88.2%, specificity from 76.1% to 84.2%, and negative predictive value (NPV) from 97.4% to 98.6%. Results were presented at The International Society for Heart and Lung Transplantation’s annual meeting and will be submitted for peer-reviewed publication.
Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. The presentation is scheduled for 7:40 a.m. PT (10:40 a.m. ET) and can be accessed via a live webcast on Natera's investor relations website. A replay will also be available post-event.
Natera (NASDAQ: NTRA) will present new data on its Prospera donor-derived cell-free DNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 from June 1–5. The company will showcase 18 abstracts, including results from the ProActive study, the largest prospective dd-cfDNA study in kidney transplant recipients. Key findings highlight the Prospera Kidney test's efficacy in predicting organ rejection, with results demonstrating a high predictive value (AUC range: 92-96%). Additional data show significant variation in dd-cfDNA levels, suggesting its utility in ongoing surveillance and risk stratification for adverse outcomes.
Natera, a global leader in cell-free DNA and genetic testing, will present at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for Thursday, May 30, 2024, at 8:40 a.m. PT (11:40 a.m. ET). The event will be live-streamed on the investor relations section of Natera's website, with a replay available shortly after.
Natera (NASDAQ: NTRA) will present new data at the 2024 ASCO Annual Meeting, May 31 – June 4, 2024. The data spans multiple cancer types, including breast, colorectal (CRC), lung, melanoma, esophageal, and urothelial cancers. Natera's Signatera™ and Empower™ tests will be highlighted in one oral and 13 poster presentations. Key studies include the CIRCULATE-Japan GALAXY study, showcasing the prognostic and predictive utility of Signatera for CRC. Natera expects topline results from the ALTAIR phase III trial by August 2024. Presentations will demonstrate ctDNA's role in detecting minimal residual disease and monitoring treatment responses in various cancers.
Natera, Inc. (NASDAQ: NTRA) reported positive first quarter financial results for 2024, with $367.7 million in total revenues, a 52.1% increase from the previous year. The company achieved a gross margin of 56.7%, processed 735,800 tests, and had a net loss of $67.6 million. Natera expects total revenue of $1.42 billion to $1.45 billion for 2024.
Natera, Inc. announced a new publication in JCO Precision Oncology showcasing the effectiveness of its Signatera test in detecting breast cancer recurrence early. The study involved 156 early-stage breast cancer patients followed for up to 12 years post-surgery. Signatera detected relapse 38 months earlier than imaging, with an 88.2% sensitivity rate. Patients testing positive for ctDNA had worse survival outcomes. The study emphasizes the importance of early recurrence detection and long-term monitoring in breast cancer patients.
Natera, Inc. (NASDAQ: NTRA) will report its first quarter 2024 results on May 9. The company is a global leader in cell-free DNA and genetic testing. The earnings conference call will take place at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Natera, Inc. (NASDAQ: NTRA) has launched a new cfDNA-based fetal RhD test to support Ob/Gyn physicians and patients during a nationwide shortage of RhIg therapy. The test offers 100% sensitivity and >99% specificity, and can be conducted as early as nine weeks gestation. This initiative is important to prevent complications from alloimmunization in pregnancies where the maternal blood type is RhD-negative and the fetal blood type is RhD-positive. The product launch was supported by a large clinical validation study with over 650 patients, demonstrating Natera's commitment to accurate and reliable diagnostics in women's health.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
What does Natera, Inc. specialize in?
Where is Natera, Inc. headquartered?
What is the Panorama Non-Invasive Prenatal Test (NIPT)?
What is the Horizon Carrier Screening (HCS)?
What is the Signatera Molecular Residual Disease (MRD) Test?
What is the purpose of the Prospera test?
How has Natera advanced genetic testing?
Does Natera offer genetic counseling services?
What industries does Natera serve?
What makes Natera's tests unique?
